vs
Amneal Pharmaceuticals, Inc.（AMRX）与Reddit, Inc.（RDDT）财务数据对比。点击上方公司名可切换其他公司
Amneal Pharmaceuticals, Inc.的季度营收约是Reddit, Inc.的1.1倍（$814.3M vs $725.6M），Reddit, Inc.净利率更高（34.7% vs 4.3%，领先30.4%），Reddit, Inc.同比增速更快（69.7% vs 11.5%），Reddit, Inc.自由现金流更多（$263.6M vs $108.5M），过去两年Reddit, Inc.的营收复合增速更高（72.8% vs 11.1%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
Reddit是美国知名的社交新闻聚合与论坛类社交媒体平台，注册用户可发布链接、文字帖、图片、视频等各类内容，其他用户可对内容进行点赞或点踩，内容按主题归类到用户创建的子板块中，获赞更高的内容会排在板块前列，热度足够的内容还将展示在全站首页。
AMRX vs RDDT — 直观对比
营收规模更大
AMRX
是对方的1.1倍
$725.6M
营收增速更快
RDDT
高出58.2%
11.5%
净利率更高
RDDT
高出30.4%
4.3%
自由现金流更多
RDDT
多$155.1M
$108.5M
两年增速更快
RDDT
近两年复合增速
11.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $814.3M | $725.6M |
| 净利润 | $35.1M | $251.6M |
| 毛利率 | 36.5% | 91.9% |
| 营业利润率 | 13.8% | 31.9% |
| 净利率 | 4.3% | 34.7% |
| 营收同比 | 11.5% | 69.7% |
| 净利润同比 | 212.9% | 254.2% |
| 每股收益（稀释后） | $0.10 | $1.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXRDDT
| Q4 25 | $814.3M | $725.6M | ||
| Q3 25 | $784.5M | $584.9M | ||
| Q2 25 | $724.5M | $499.6M | ||
| Q1 25 | $695.4M | $392.4M | ||
| Q4 24 | $730.5M | $427.7M | ||
| Q3 24 | $702.5M | $348.4M | ||
| Q2 24 | $701.8M | $281.2M | ||
| Q1 24 | $659.2M | $243.0M |
净利润AMRXRDDT
| Q4 25 | $35.1M | $251.6M | ||
| Q3 25 | $2.4M | $162.7M | ||
| Q2 25 | $22.4M | $89.3M | ||
| Q1 25 | $12.2M | $26.2M | ||
| Q4 24 | $-31.1M | $71.0M | ||
| Q3 24 | $-156.0K | $29.9M | ||
| Q2 24 | $6.0M | $-10.1M | ||
| Q1 24 | $-91.6M | $-575.1M |
毛利率AMRXRDDT
| Q4 25 | 36.5% | 91.9% | ||
| Q3 25 | 34.9% | 91.0% | ||
| Q2 25 | 39.5% | 90.8% | ||
| Q1 25 | 36.8% | 90.5% | ||
| Q4 24 | 36.0% | 92.6% | ||
| Q3 24 | 38.4% | 90.1% | ||
| Q2 24 | 35.6% | 89.5% | ||
| Q1 24 | 36.1% | 88.6% |
营业利润率AMRXRDDT
| Q4 25 | 13.8% | 31.9% | ||
| Q3 25 | 9.0% | 23.7% | ||
| Q2 25 | 15.4% | 13.6% | ||
| Q1 25 | 14.4% | 1.0% | ||
| Q4 24 | 10.4% | 12.4% | ||
| Q3 24 | 12.6% | 2.0% | ||
| Q2 24 | 13.6% | -11.0% | ||
| Q1 24 | -1.6% | -242.5% |
净利率AMRXRDDT
| Q4 25 | 4.3% | 34.7% | ||
| Q3 25 | 0.3% | 27.8% | ||
| Q2 25 | 3.1% | 17.9% | ||
| Q1 25 | 1.8% | 6.7% | ||
| Q4 24 | -4.3% | 16.6% | ||
| Q3 24 | -0.0% | 8.6% | ||
| Q2 24 | 0.9% | -3.6% | ||
| Q1 24 | -13.9% | -236.7% |
每股收益（稀释后）AMRXRDDT
| Q4 25 | $0.10 | $1.24 | ||
| Q3 25 | $0.01 | $0.80 | ||
| Q2 25 | $0.07 | $0.45 | ||
| Q1 25 | $0.04 | $0.13 | ||
| Q4 24 | $-0.10 | $4.76 | ||
| Q3 24 | $0.00 | $0.16 | ||
| Q2 24 | $0.02 | $-0.06 | ||
| Q1 24 | $-0.30 | $-8.19 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.0M | $953.6M |
| 总债务越低越好 | $2.6B | — |
| 股东权益账面价值 | $-70.8M | $2.9B |
| 总资产 | $3.7B | $3.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMRXRDDT
| Q4 25 | $282.0M | $953.6M | ||
| Q3 25 | $201.2M | $911.7M | ||
| Q2 25 | $71.5M | $734.1M | ||
| Q1 25 | $59.2M | $635.7M | ||
| Q4 24 | $110.6M | $562.1M | ||
| Q3 24 | $74.0M | $515.9M | ||
| Q2 24 | $43.8M | $468.0M | ||
| Q1 24 | $46.5M | $968.5M |
总债务AMRXRDDT
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.4B | — |
股东权益AMRXRDDT
| Q4 25 | $-70.8M | $2.9B | ||
| Q3 25 | $-109.5M | $2.6B | ||
| Q2 25 | $-112.1M | $2.4B | ||
| Q1 25 | $-131.7M | $2.2B | ||
| Q4 24 | $-109.3M | $2.1B | ||
| Q3 24 | $-93.4M | $2.0B | ||
| Q2 24 | $-57.5M | $1.9B | ||
| Q1 24 | $-63.7M | $1.8B |
总资产AMRXRDDT
| Q4 25 | $3.7B | $3.2B | ||
| Q3 25 | $3.6B | $2.9B | ||
| Q2 25 | $3.4B | $2.6B | ||
| Q1 25 | $3.4B | $2.4B | ||
| Q4 24 | $3.5B | $2.3B | ||
| Q3 24 | $3.5B | $2.2B | ||
| Q2 24 | $3.5B | $2.1B | ||
| Q1 24 | $3.5B | $2.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $130.3M | $266.8M |
| 自由现金流经营现金流 - 资本支出 | $108.5M | $263.6M |
| 自由现金流率自由现金流/营收 | 13.3% | 36.3% |
| 资本支出强度资本支出/营收 | 2.7% | 0.4% |
| 现金转化率经营现金流/净利润 | 3.72× | 1.06× |
| 过去12个月自由现金流最近4个季度 | $269.9M | $684.2M |
8季度趋势，按日历期对齐
经营现金流AMRXRDDT
| Q4 25 | $130.3M | $266.8M | ||
| Q3 25 | $118.5M | $185.2M | ||
| Q2 25 | $83.8M | $111.3M | ||
| Q1 25 | $7.4M | $127.6M | ||
| Q4 24 | $118.1M | $90.0M | ||
| Q3 24 | $141.8M | $71.6M | ||
| Q2 24 | $39.7M | $28.4M | ||
| Q1 24 | $-4.4M | $32.1M |
自由现金流AMRXRDDT
| Q4 25 | $108.5M | $263.6M | ||
| Q3 25 | $106.2M | $183.1M | ||
| Q2 25 | $61.0M | $110.8M | ||
| Q1 25 | $-5.8M | $126.6M | ||
| Q4 24 | $102.9M | $89.2M | ||
| Q3 24 | $124.8M | $70.3M | ||
| Q2 24 | $29.0M | $27.2M | ||
| Q1 24 | $-13.6M | $29.2M |
自由现金流率AMRXRDDT
| Q4 25 | 13.3% | 36.3% | ||
| Q3 25 | 13.5% | 31.3% | ||
| Q2 25 | 8.4% | 22.2% | ||
| Q1 25 | -0.8% | 32.3% | ||
| Q4 24 | 14.1% | 20.8% | ||
| Q3 24 | 17.8% | 20.2% | ||
| Q2 24 | 4.1% | 9.7% | ||
| Q1 24 | -2.1% | 12.0% |
资本支出强度AMRXRDDT
| Q4 25 | 2.7% | 0.4% | ||
| Q3 25 | 1.6% | 0.4% | ||
| Q2 25 | 3.2% | 0.1% | ||
| Q1 25 | 1.9% | 0.2% | ||
| Q4 24 | 2.1% | 0.2% | ||
| Q3 24 | 2.4% | 0.4% | ||
| Q2 24 | 1.5% | 0.4% | ||
| Q1 24 | 1.4% | 1.2% |
现金转化率AMRXRDDT
| Q4 25 | 3.72× | 1.06× | ||
| Q3 25 | 50.00× | 1.14× | ||
| Q2 25 | 3.74× | 1.25× | ||
| Q1 25 | 0.61× | 4.88× | ||
| Q4 24 | — | 1.27× | ||
| Q3 24 | — | 2.40× | ||
| Q2 24 | 6.62× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
| Oral Solid | $188.7M | 23% |
| Distribution Service | $107.7M | 13% |
| Central Nervous System | $104.8M | 13% |
| Government Label | $86.8M | 11% |
| Other Dosage Forms | $68.2M | 8% |
| Transdermal | $56.1M | 7% |
| Hormonal Allergy | $47.6M | 6% |
| Ephinephrine Auto Injector | $39.1M | 5% |
| Injectable | $37.4M | 5% |
| Other | $33.6M | 4% |
| Biosimilar | $29.4M | 4% |
| Selling General And Administrative Expenses | $14.9M | 2% |
RDDT
| Advertising | $689.7M | 95% |
| Other Revenue | $35.9M | 5% |
